Statements (109)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
No
Acquired by a private equity firm in 2018 |
| gptkbp:advertising |
Focused on oncology
|
| gptkbp:budget |
Available online
|
| gptkbp:businessModel |
Biopharmaceutical
Biopharmaceutical development |
| gptkbp:CEO |
Brent_L._R._Stockwell
|
| gptkbp:clinicalTrials |
Ongoing
Yes Phase 2 Innovative approaches Ongoing clinical trials Phase 2 trials Published in journals Promising results Phase 1, Phase 2 Conducting trials in multiple phases Late-stage clinical trials Phase 1 and Phase 2 studies Positive clinical trial outcomes Published clinical trial results |
| gptkbp:collaborations |
Academic institutions
Yes Collaboration with pharmaceutical companies Collaboration with academic institutions With leading institutions With biotech firms |
| gptkbp:community_engagement |
Active
|
| gptkbp:community_service |
Engaged with communities
Programs for cancer patients Progression-free survival |
| gptkbp:communityEngagement |
Involvement in cancer awareness initiatives
|
| gptkbp:communityPartnerships |
Collaborations with research institutions
Strategic alliances with other companies |
| gptkbp:corporateSocialResponsibility |
Commitment to ethical practices.
|
| gptkbp:drugInterdiction |
In various stages of development
Prioritized in development |
| gptkbp:employees |
Approximately 100
|
| gptkbp:feedback |
Improving through therapies
|
| gptkbp:financialPerformance |
Publicly reported
|
| gptkbp:financials |
Regularly conducted
Quarterly earnings reports |
| gptkbp:focus |
Oncology
cancer therapeutics |
| gptkbp:founded |
2004
|
| gptkbp:founder |
Arlene_Morris
|
| gptkbp:funding |
Venture capital funding
Secured from various sources |
| gptkbp:future_plans |
Positive
Expand product pipeline |
| gptkbp:hasPrograms |
Diverse experts in oncology
|
| gptkbp:hasResearchInterest |
Conducting market analysis for oncology drugs
|
| gptkbp:headquarters |
gptkb:Waltham,_Massachusetts
|
| gptkbp:historicalResearch |
Partnerships with biotech firms
|
| https://www.w3.org/2000/01/rdf-schema#label |
Syndax Pharmaceuticals
|
| gptkbp:impact |
Targeted therapies
|
| gptkbp:investmentFocus |
Active
High Institutional investors Publicly traded company Various venture capital firms Regular updates to investors Significant funding rounds Annual shareholder meetings |
| gptkbp:is_aimed_at |
Various cancers
|
| gptkbp:leadership |
Experienced management team
|
| gptkbp:market |
Cancer treatment
Solid tumors Growing in oncology sector Growing presence in the oncology market New drug launches planned |
| gptkbp:marketSegment |
Focus on niche oncology markets
|
| gptkbp:mission |
Develop innovative therapies for cancer
|
| gptkbp:partnerships |
gptkb:Merck_&_Co.
Yes Pharmaceutical companies Strategic alliances |
| gptkbp:patentCitation |
Multiple patents granted
|
| gptkbp:patentType |
Yes
Entinostat for breast cancer |
| gptkbp:products |
Entinostat
Innovative drug development processes SNDX-5613 |
| gptkbp:publications |
Numerous
|
| gptkbp:regulatoryCompliance |
Ongoing
Pursuing for multiple candidates Investigational_New_Drug_(IND)_status Submissions_to_FDA_and_other_agencies |
| gptkbp:research |
Grants for cancer research
Ongoing in epigenetics. |
| gptkbp:research_areas |
Oncology
Hematologic malignancies Multiple cancer types Solid tumors Focused on unmet needs Entinostat, SNDX-6352 |
| gptkbp:research_focus |
Epigenetics
|
| gptkbp:researchFocus |
Epigenetic therapies
|
| gptkbp:researchInterest |
Research published in peer-reviewed journals
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
SNDX
|
| gptkbp:strategicGoals |
Expand product pipeline
|
| gptkbp:supplyChain |
Entinostat
|
| gptkbp:supportRole |
Established
|
| gptkbp:team |
Diverse backgrounds
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
Multiple drug candidates
|
| gptkbp:website |
www.syndax.com
|